Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ErbB3

ErbB3

Brief Information

Name:Receptor tyrosine-protein kinase erbB-3
Target Synonym:EC:2.7.10.1,EC 2.7.10,Tyrosine Kinase-Type Cell Surface Receptor HER3,Lethal Congenital Contracture Syndrome 2,FERLK,P45-SErbB3,P85-SErbB3,MDA-BF-1,C-ErbB-3,Proto-oncogene-like protein c-ErbB-3,HER3,ERBB3,Erb-B2 Receptor Tyrosine Kinase 3,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3,Human Epidermal Growth Factor Receptor 3,Receptor Tyrosine-Protein Kinase ErbB-3,EC 2.7.10.1,P180-ErbB3,C-ErbB3,ErbB3-S,ErbB-3,LCCS2,Receptor, ErbB-3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

ER3-H82E6-ELISA
Biotinylated Human ErbB3, His,AvitagBiotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) ELISA bioactivity

Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).

ER3-H82E6-MALS-HPLC
Biotinylated Human ErbB3, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) is more than 90% and the molecular weight of this protein is around 78-106 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human ErbB3, His,AvitagBiotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) ELISA bioactivity

Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).

Synonym Name

ERBB3,HER3,LCCS2,MDA-BF-1,MGC88033,c-erbB3,erbB3-S,p180-ErbB3,p45-sErbB3,p85-sErbB3

Background

ErbB3,also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation. However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Osimertinib Mesylate AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 Approved Astrazeneca Pharmaceutical Co Ltd 泰瑞沙, Tagrisso Mainland China Carcinoma, Non-Small-Cell Lung Astrazeneca Ab 2015-11-13 Solid tumours; Carcinoma, Bronchogenic; Carcinoma; Thoracic Neoplasms; Bronchial Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GSK-2849330 GSK-2849330 Phase 1 Clinical Glaxosmithkline Plc Neoplasms Details
Lumretuzumab RG-7116; RO-5479599 Phase 2 Clinical F. Hoffmann-La Roche Ltd Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) SAL-007 Phase 1 Clinical Shenzhen Salubris Pharmaceuticals Co Ltd Heart Failure Details
Zenocutuzumab MCLA-128 Phase 2 Clinical Merus Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MP-0274 DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 Phase 1 Clinical Molecular Partners Ag Neoplasms Details
Sapitinib AZD-8931 Phase 2 Clinical Astrazeneca Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis Details
Sirotinib Maleate XZP-5491 Phase 1 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
Tesevatinib KD-019; KD-020; XL-647; EXEL-7647 Phase 3 Clinical Exelixis Inc Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Carcinoma, Non-Small-Cell Lung; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis Details
Recombinant human ErbB3 fragment vaccine (Zensun) rhErbB3-f Phase 1 Clinical Zensun (Shanghai) Sci&Tech Co Ltd Neoplasms Details
AV-203 AV-203; CAN-017 Phase 1 Clinical Aveo Solid tumours; Neoplasms Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase 2 Clinical Shanghai Allist Pharmaceutical Technology Co Ltd Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Barecetamab ISU-104 Phase 1 Clinical Isu Abxis Solid tumours Details
KTN-3379 CDX-3379; KTN-3379 Phase 2 Clinical Medimmune Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms; Thyroid Neoplasms Details
Seribantumab MM-121; SAR-256212; 1N3L70MDFX (UNII code) Phase 2 Clinical Merrimack Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Gallbladder Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Cholangiocarcinoma; Solid tumours; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Kidney Neoplasms Details
SI-B001 SI-B001 Phase 3 Clinical Sichuan Baili Pharmaceutical Co Ltd Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
Patritumab Deruxtecan U3-1402 Phase 2 Clinical Daiichi Sankyo Co Ltd Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
HMBD-001 HMBD-001 Phase 2 Clinical Hummingbird Bioscience Solid tumours; Neoplasms Details
BL-B01D1 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Neoplasms, Fibroepithelial; Solid tumours; Digestive System Neoplasms; Urologic Neoplasms Details
SIBP-03 SIBP-03 Phase 1 Clinical Shanghai Institute Of Biological Products Co Ltd Neoplasms Details
Recombinat humanized HER3-targeting antibody Phase 1 Clinical Shanghai Institute Of Biological Products Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message